🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› USA
Clinical trial register · United States · industry-sponsored

Industry-sponsored studies with a US investigative site

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9115 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 24 Sep 2026, 03:16 UTC
9115
Studies in scope
industry-sponsored, all four open statuses
4955
Recruiting now
open to new participants
2206
Lead sponsors
across recruiting studies
Top states
California 230 Florida 173 Arizona 111 Illinois 110 Georgia 104
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca299 Novartis Pharmaceuticals202 Eli Lilly and Company189 Merck Sharp & Dohme LLC182 AbbVie172 Clear sponsor filter
State
California230 Florida173 Arizona111 Illinois110 Georgia104
All 47 states
Target enrolment
to

Trials in this register

299 of 9115 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases
NCT06512883Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilia Syndrome (HES)
AstraZeneca
Phase 3
14
Colorado, Ohio
2025-04-17
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
NCT06868277Carcinoma, Non-Small Cell Lung
AstraZeneca
Phase 3
830
California, Delaware, Florida, Georgia, Illinois, Iowa, Kansas, Kentucky
2025-04-10
Recruiting
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment
NCT06750289Eosinophilic Asthma
AstraZeneca
Phase 3
400
Arizona, California, Colorado, Florida, Michigan, Nevada, New Jersey, New York
2025-03-28
Recruiting
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
NCT06989112Endometrial Cancer
AstraZeneca
Phase 3
600
Arizona, Arkansas, California, Florida, Georgia, Hawaii, Illinois, Louisiana
2025-03-27
Recruiting
First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
NCT06795022Hepatocellular Carcinoma
AstraZeneca
Phase 1/2
304
California, Maryland, Massachusetts, Missouri, New Jersey, Texas
2025-03-27
Recruiting
Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids
NCT06932263Asthma
AstraZeneca
Phase 2
540
California, Delaware, Florida, Idaho, Indiana, Iowa, Kansas, Kentucky
2025-03-26
Recruiting
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
NCT06878261Chronic Obstructive Pulmonary Disease (COPD)
AstraZeneca
Phase 3
990
Alabama, Arizona, California, Connecticut, Delaware, Florida, Georgia, Illinois
2025-03-25
Recruiting
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
NCT06883305Chronic Obstructive Pulmonary Disease (COPD)
AstraZeneca
Phase 3
990
Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Indiana
2025-03-18
Recruiting
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT06677060Heart Failure
AstraZeneca
Phase 3
11,300
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia
2025-03-14
Recruiting
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
NCT06792695Metastatic Colorectal Cancer
AstraZeneca
Phase 2
80
Arizona, California, District of Columbia, Illinois, Maryland, Massachusetts, Minnesota, New Jersey
2025-03-12
Active, closed
Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist
NCT06851858Endocrinology, Diabetes, Type II, Obesity
AstraZeneca
Phase 2
69
Alabama, Florida, Georgia, Illinois, Kansas, Kentucky, Missouri, Nevada
2025-03-12
Recruiting
A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT06879041Metastatic Castration-Resistant Prostate Cancer
AstraZeneca
Phase 1
136
California, Florida, Illinois, Louisiana, Massachusetts, Minnesota, Nebraska, New York
2025-03-10
Active, closed
Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease
NCT06824987APOL1-Mediated Kidney Disease
AstraZeneca
Phase 2
57
Alabama, Arizona, California, Florida, Georgia, Illinois, Louisiana, Maryland
2025-03-05
Active, closed
An Ophthalmic Safety Study in Patients With Breast Cancer
NCT06767462Ophthalmic Safety in Patients With Breast Cancer
AstraZeneca
Observational
160
California, Iowa, North Carolina, Pennsylvania, South Dakota, Tennessee, Texas
2025-03-05
Recruiting
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
NCT06742723Chronic Kidney Disease and Hypertension
AstraZeneca
Phase 3
5,000
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-03-03
Recruiting
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
NCT06764875HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
AstraZeneca
Phase 3
840
Alaska, Arizona, California, Colorado, Delaware, Florida, Georgia, Illinois
2025-03-01
Recruiting
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
NCT06651970Chronic Lymphocytic Leukaemia, Moderate to Severe Cardiac Impairment
AstraZeneca
Phase 4
60
North Carolina, Ohio, Pennsylvania
2025-02-04
Recruiting
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
NCT06564038Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma
AstraZeneca
Phase 1/2
408
Massachusetts, New Jersey, New York, North Carolina, Ohio, Oregon, Pennsylvania, Rhode Island
2025-01-30
Recruiting
A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)
NCT06749457Staphylococcus Aureus
AstraZeneca
Phase 1/2
231
Alabama, California, Colorado, Florida, Georgia, Illinois, Iowa, Kentucky
2024-12-30
Active, closed
A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab
NCT06706817Chronic Rhinosinusitis With Nasal Polyps
AstraZeneca
Phase 3
181
California, Illinois, Massachusetts, Missouri
2024-12-03
Recruiting
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
NCT06526793B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)
AstraZeneca
Phase 2
270
Arizona, California, Florida, Illinois, Iowa, Kansas, Minnesota, Missouri
2024-11-27
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
NCT06627647Non-squamous Non-small Cell Lung Cancer
AstraZeneca
Phase 3
1,160
Alabama, Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia
2024-11-27
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738Non-small Cell Lung Cancer
AstraZeneca
Phase 3
1,160
Arizona, Arkansas, California, Connecticut, Delaware, Florida, Georgia, Idaho
2024-11-18
Active, closed
A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features
NCT06564844Non-small Cell Lung Cancer
AstraZeneca
Phase 3
25
Arizona, California, Colorado, District of Columbia, Florida, Illinois, Kansas, Kentucky
2024-10-15
Recruiting
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06417814Metastatic Non-small Cell Lung Cancer
AstraZeneca
Phase 3
744
Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Kentucky
2024-10-04
Active, closed
Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.
NCT06473779Severe Asthma
AstraZeneca
Phase 3
326
California, Colorado, Florida, Massachusetts, Missouri, New Jersey, Oklahoma, Texas
2024-09-30
Recruiting
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
NCT06542250B-cell Malignancies
AstraZeneca
Phase 1/2
174
California, Massachusetts, Minnesota, New Jersey, New York, North Carolina, Texas, Washington
2024-09-18
Active, closed
Phase IIa Study Evaluating AZD7798 in Crohn's Disease
NCT06450197Moderate to Severe Crohn's Disease
AstraZeneca
Phase 2
120
Arizona, California, Florida, Idaho, Kansas, Michigan, Missouri, North Carolina
2024-08-28
Active, closed
Volrustomig Priming Regimens Exploratory Phase II Platform Study
NCT06448754Non-small Cell Lung Cancer
AstraZeneca
Phase 2
194
California, North Carolina
2024-08-27
Recruiting
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
NCT06535607Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
AstraZeneca
Phase 2
257
California, Maryland, New York, Ohio, Pennsylvania
2024-08-22
Recruiting
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
NCT06467357Biliary Tract Cancer
AstraZeneca
Phase 3
620
Arizona, California, District of Columbia, Florida, Georgia, Idaho, Illinois, Maryland
2024-08-12
Recruiting
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
NCT06549595Untreated Follicular Lymphoma
AstraZeneca
Phase 3
1,018
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Delaware, Florida
2024-08-07
Recruiting
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
NCT06380751Advanced Breast Cancer
AstraZeneca
Phase 3
788
Arizona, California, Colorado, Florida, Illinois, Indiana, Kentucky, Maryland
2024-08-01
Active, closed
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
NCT06147037Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer
AstraZeneca
Phase 1
13
California, Illinois, Nebraska, Ohio, Texas, Washington
2024-07-31
Recruiting
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
NCT05952024Diffuse Large B-Cell Lymphoma
AstraZeneca
Phase 2
80
California, Connecticut, Florida, Iowa, Kentucky, Maryland, Michigan, South Dakota
2024-07-16
Active, closed
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
NCT06015737Cutaneous Lupus Erythematosus
AstraZeneca
Phase 3
339
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Indiana
2024-06-29
Recruiting
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
NCT06465810Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR
AstraZeneca
Observational
1,850
California, Connecticut, District of Columbia, Illinois, Indiana, Maryland, Massachusetts, Minnesota
2024-06-25
Recruiting
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
NCT06455449Polymyositis, Dermatomyositis
AstraZeneca
Phase 3
240
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2024-06-20
Recruiting
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
NCT06307665Asthma
AstraZeneca
Phase 3
440
Alaska, Arizona, Arkansas, California, Colorado, Delaware, Florida, Georgia
2024-05-20
Active, closed
Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care
NCT06422689Asthma
AstraZeneca
Phase 4
1,511
California, Kentucky, Massachusetts, Michigan, Minnesota, North Carolina, Pennsylvania, Texas
2024-05-10
Recruiting
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT06350097Non-small Cell Lung Cancer
AstraZeneca
Phase 3
582
California, Connecticut, District of Columbia, Florida, Hawaii, Illinois, Indiana, Maryland
2024-04-29
Active, closed
To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations
NCT06194448Lung Cancer
AstraZeneca
Phase 2
76
California
2024-04-21
Recruiting
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
NCT06307652Heart Failure and Impaired Kidney Function
AstraZeneca
Phase 3
3,850
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois
2024-04-12
Recruiting
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
NCT06357533Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
675
Alaska, Arizona, Arkansas, California, Florida, Georgia, Illinois, Indiana
2024-04-11
Active, closed
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
NCT06008093Carcinoma, Non-Small-Cell Lung
AstraZeneca
Phase 2
103
California, District of Columbia, Florida, Georgia, Hawaii, Illinois, Maryland, Massachusetts
2024-04-04
Active, closed
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
NCT06268873Chronic Kidney Disease and Hypertension
AstraZeneca
Phase 3
2,554
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2024-03-29
Recruiting
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
NCT06218914Non-small Cell Lung Cancer, Colorectal Carcinoma, Pancreatic Ductal Adenocarcinoma, Endometrial Cancer
AstraZeneca
Phase 1
108
California, Florida, Illinois, Kansas, Massachusetts, Missouri, New York, Oregon
2024-03-22
Recruiting
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
NCT05835310Systemic Lupus Erythematosus
AstraZeneca
Phase 3
100
Arizona, California, District of Columbia, Illinois, Louisiana, Maryland, Minnesota, New York
2024-03-14
Recruiting
Study of AZD0754 in Participants With Metastatic Prostate Cancer
NCT06267729Metastatic Prostate Cancer
AstraZeneca
Phase 1/2
60
California, Florida, Georgia, Kansas, Massachusetts, Missouri, New Jersey, New York
2024-03-12
Active, closed
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
NCT06346392Gastric Cancer, Gastroesophageal Junction Cancer
AstraZeneca
Phase 3
594
Alabama, Arizona, California, District of Columbia, Florida, Georgia, Idaho, Kentucky
2024-03-04
Active, closed
Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)
NCT05925530Non-small Cell Lung Cancer
AstraZeneca
Phase 2
142
New York, Texas, Virginia
2024-02-22
Recruiting
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
NCT06283966COPD (Chronic Obstructive Pulmonary Disease)
AstraZeneca
Phase 3
5,000
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Idaho
2024-02-21
Active, closed
A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE
NCT06040099Hepatocellular Carcinoma (HCC)
AstraZeneca
Phase 2
58
Colorado, Florida, Georgia, Illinois, Massachusetts, Michigan, Missouri, New Jersey
2024-02-13
Recruiting
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
NCT06137144Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL)
AstraZeneca
Phase 1/2
161
California, Florida, Georgia, Massachusetts, New York, Pennsylvania, Texas
2024-01-23
Recruiting
A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors
NCT06130553Advanced Solid Tumors That Are MTAP Deficient
AstraZeneca
Phase 1/2
334
California, Connecticut, Maryland, Oregon, Pennsylvania, Rhode Island, Virginia
2024-01-18
Active, closed
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With Dyslipidemia
NCT06238466Cardiovascular
AstraZeneca
Phase 1
98
California, Florida, Maryland, Texas
2024-01-16
Recruiting
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
NCT06137118B-cell Acute Lymphoblastic Leukemia (B-ALL)
AstraZeneca
Phase 1/2
255
Alabama, California, Florida, Georgia, Illinois, New York, Texas, Virginia
2023-12-29
Recruiting
Observational Study Protocol: LIVER-R
NCT06252753Hepatobiliary Cancers
AstraZeneca
Observational
4,000
Alabama, Arizona, California, Florida, Georgia, Illinois, Louisiana, Massachusetts
2023-12-20
Recruiting
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
NCT06129864Locally Advanced Head and Neck Squamous Cell Carcinoma
AstraZeneca
Phase 3
1,145
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Illinois
2023-12-14
Active, closed
A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma
NCT06084884Hepatocellular Carcinoma
AstraZeneca
Phase 1/2
94
Arizona, California, District of Columbia, Florida, Georgia, Kansas, Minnesota, New Jersey
2023-12-14
Recruiting
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
NCT06219941Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
AstraZeneca
Phase 2
226
California, Kentucky, New York, Rhode Island, Texas
2023-12-13
Active, closed
A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma
NCT05951959Mantle Cell Lymphoma (MCL)
AstraZeneca
Phase 2
108
New Jersey, New York, Ohio, Pennsylvania, Texas
2023-12-13
Recruiting
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
NCT06106945Multiple Myeloma
AstraZeneca
Phase 1/2
226
California, Georgia, Massachusetts, Michigan, Missouri, New York, Pennsylvania, Virginia
2023-12-05
Recruiting
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
NCT06188520ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC)
AstraZeneca
Phase 1/2
564
Missouri, Rhode Island, Tennessee, Texas
2023-12-05
Active, closed
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
NCT06109779Biliary Tract Cancer
AstraZeneca
Phase 3
760
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2023-12-04
Recruiting
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
NCT06103864Breast Cancer
AstraZeneca
Phase 3
625
Alabama, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2023-11-23
Active, closed
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
NCT06120491Metastatic Castration-Sensitive Prostate Cancer
AstraZeneca
Phase 3
1,898
Arizona, Arkansas, California, Colorado, Connecticut, Georgia, Illinois, Indiana
2023-11-21
Active, closed
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
NCT06112379Breast Cancer
AstraZeneca
Phase 3
1,902
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2023-11-14
Active, closed
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
NCT06097728Unresectable Pleural Mesothelioma
AstraZeneca
Phase 3
863
California, Colorado, Florida, Georgia, Illinois, Minnesota, Missouri, New York
2023-11-09
Active, closed
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
NCT05925803Systemic Sclerosis, Scleroderma
AstraZeneca
Phase 3
314
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Kansas
2023-11-08
Active, closed
Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)
NCT06087835Chronic Kidney Disease With High Proteinuria
AstraZeneca
Phase 3
1,835
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kentucky
2023-11-07
Active, closed
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
NCT05984277Metastatic Non-small Cell Lung Cancer
AstraZeneca
Phase 3
895
Arkansas, California, Colorado, Florida, Indiana, Iowa, Kentucky, Maryland
2023-10-24
Active, closed
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
NCT05952557Breast Cancer, Early Breast Cancer
AstraZeneca
Phase 3
5,511
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida
2023-10-05
Recruiting
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
NCT06079671Locally Advanced Cervical Cancer
AstraZeneca
Phase 3
800
Alabama, Arizona, Arkansas, California, Georgia, Illinois, Indiana, Louisiana
2023-09-22
Recruiting
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
NCT06023589Asthma
AstraZeneca
Phase 3
231
Alabama, Arizona, Arkansas, California, Georgia, Maryland, Massachusetts, Michigan
2023-08-24
Recruiting
OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis
NCT06355934ATTR Amyloidosis
AstraZeneca
Observational
52,121
Minnesota
2023-08-21
Active, closed
Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)
NCT05771480Biliary Tract Cancer
AstraZeneca
Phase 3
142
Alabama, California, District of Columbia, Oregon
2023-08-16
Active, closed
BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants
NCT05943106Non-Muscle- Invasive Bladder Cancer
AstraZeneca
Phase 3
100
Arizona, Arkansas, California, Colorado, Florida, Indiana, Kansas, Maryland
2023-08-11
Recruiting
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
NCT05850234Relapsed/Refractory Multiple Myeloma
AstraZeneca
Phase 1/2
232
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Iowa
2023-07-20
Recruiting
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
NCT05877599Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma, Pancreatic Adenocarcinoma
AstraZeneca
Phase 1
45
Arizona, California, Florida, Massachusetts, New Jersey, New York, North Carolina, Oregon
2023-07-12
Recruiting
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
NCT06005493Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma
AstraZeneca
Phase 1/2
280
Florida, Minnesota, New York
2023-07-11
Active, closed
Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)
NCT05883644Advanced Hepatocellular Carcinoma
AstraZeneca
Phase 3
111
California, Louisiana, Michigan
2023-06-27
Recruiting
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
NCT05797168Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer, Lung Squamous Cell Carcinoma
AstraZeneca
Phase 1/2
602
California, Colorado, Kentucky, Massachusetts, Michigan, Ohio, Oregon, Rhode Island
2023-06-05
Active, closed
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
NCT05775159Hepatocellular Carcinoma, Biliary Tract Cancer
AstraZeneca
Phase 2
294
Alabama, California, Kansas, New York
2023-04-24
Active, closed
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma
NCT05692180Asthma
AstraZeneca
Phase 3
94
California, Florida, Kentucky, Louisiana, Missouri, New Jersey, New York, Ohio
2023-04-05
Recruiting
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
NCT05774951Breast Cancer, Early Breast Cancer
AstraZeneca
Phase 3
4,300
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Florida
2023-03-31
Active, closed
A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)
NCT05526755Stage II-IIIB Non-small Cell Lung Carcinoma
AstraZeneca
Phase 2
188
California, Nevada, New York
2023-03-06
Recruiting
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT05702229Gastric Cancer
AstraZeneca
Phase 2
163
California, Louisiana, Michigan, New York, Pennsylvania
2023-01-16
Active, closed
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
NCT05687266NSCLC
AstraZeneca
Phase 3
1,350
Arizona, Arkansas, California, Colorado, Florida, Illinois, Indiana, Iowa
2022-12-29
Active, closed
First in Human Study of AZD9592 in Solid Tumors
NCT05647122Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms
AstraZeneca
Phase 1
167
California, Connecticut, District of Columbia, Illinois, Maryland, Massachusetts, New York, Pennsylvania
2022-12-21
Recruiting
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
NCT05624450Viral Lung Infection and Acute Respiratory Failure
AstraZeneca
Phase 3
3,527
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Idaho
2022-12-13
Active, closed
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
NCT05629585Breast Cancer
AstraZeneca
Phase 3
1,174
Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida
2022-11-28
Active, closed
Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis
NCT05583227Eosinophilic Esophagitis
AstraZeneca
Phase 3
368
Arizona, Arkansas, California, Colorado, Florida, Illinois, Iowa, Kansas
2022-11-10
Active, closed
Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer
NCT05498155Breast Cancer
AstraZeneca
Phase 2
50
Colorado, Massachusetts, Oregon, Pennsylvania
2022-11-07
Active, closed
A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy
NCT05450692Advanced or Metastatic Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
594
Alabama, Arizona, California, Florida, Georgia, Indiana, Maryland, Mississippi
2022-09-15
Active, closed
A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT05057494Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
AstraZeneca
Phase 3
607
Arizona, California, Colorado, Florida, Massachusetts, Minnesota, Missouri, New York
2022-09-12
Recruiting
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
NCT05489211Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer
AstraZeneca
Phase 2
454
California, Indiana, Kansas, Massachusetts, Michigan, New Jersey, New Mexico, New York
2022-09-06
Active, closed
A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition
NCT05061134Melanoma
AstraZeneca
Phase 2
194
California, Florida, Maryland, Tennessee
2022-08-11
Active, closed
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
NCT05261399Carcinoma, Non-Small-Cell Lung
AstraZeneca
Phase 3
341
Florida, Hawaii, New Jersey, New York, Tennessee
2022-08-03
Active, closed
Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.
NCT05267613Erosive Esophagitis
AstraZeneca
Phase 3
53
Alabama, California, Florida, Indiana, Louisiana, New York, Ohio, Wisconsin
2022-07-01
Rows per page Showing 101–200 of 299
Previous 1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-usa?page=2

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,115 studies in total at the last sync on 24 Sep 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 299 of those studies that match the filters currently applied.

How many clinical trials are recruiting in the US?

147 of the 299 studies on this page are recruiting new participants as of the 24 Sep 2026, 03:16 UTC sync. A further 5 have not yet opened recruitment, 146 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

→

Browse trials by condition

Breast Cancer (14) Non-Small Cell Lung Cancer (11) Non-small Cell Lung Cancer (11) Asthma (9) Hepatocellular Carcinoma (9) Gastric Cancer (9) Systemic Lupus Erythematosus (8) Healthy Participants (8) Biliary Tract Cancer (7) Prostate Cancer (6) Ovarian Cancer (6) Endometrial Cancer (6) Type 2 Diabetes Mellitus (5) Metastatic Prostate Cancer (5) Gastroesophageal Junction Cancer (4)
→

Browse trials by state

California (230) Florida (173) Arizona (111) Illinois (110) Georgia (104) Colorado (88) New York (86) Maryland (77) Massachusetts (70) Alabama (69) Connecticut (58) Texas (53) Michigan (53) Missouri (47) District of Columbia (44)
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.